Publications by authors named "A Kentos"

Article Synopsis
  • The IMWG frailty index shows that frailty levels in patients undergoing anti-myeloma treatment can change frequently over time.
  • Assessing frailty dynamically during treatment provides better predictions for survival and early mortality than just looking at initial frailty levels.
  • The study references two clinical trials, HOVON 143 (NTR6297) and HOVON 123 (NTR4244), related to this research.
View Article and Find Full Text PDF

Purpose: Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly because of a high discontinuation rate due to toxicity. We designed a phase II trial specifically for frail patients, evaluating the efficacy and tolerability of ixazomib-daratumumab-low-dose-dexamethasone (Ixa-Dara-dex).

Methods: Sixty-five patients, who were frail according to the International Myeloma Working Group frailty index, were treated with nine induction cycles Ixa-Dara-dex followed by maintenance with Ixa-Dara for a maximum of 2 years.

View Article and Find Full Text PDF

With the introduction of immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies, major improvements have been achieved in the treatment of multiple myeloma (MM), with a significant impact on the outcome of this disease. Different treatment combinations are now in use and other therapies are being developed. Based on an extensive review of the recent literature, we propose practical recommendations on myeloma management, to be used by hematologists as a reference for daily practice.

View Article and Find Full Text PDF